HC Wainwright Reiterates “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)

HC Wainwright reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a report published on Wednesday,Benzinga reports. The firm currently has a $47.00 price target on the stock.

Several other equities analysts have also recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Chardan Capital restated a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $23.00.

Stoke Therapeutics Stock Down 6.9 %

Shares of Stoke Therapeutics stock opened at $8.26 on Wednesday. The firm has a market cap of $437.51 million, a PE ratio of -3.93 and a beta of 0.99. The company’s fifty day simple moving average is $9.50 and its two-hundred day simple moving average is $11.51. Stoke Therapeutics has a 12-month low of $5.60 and a 12-month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38. The company had revenue of $22.61 million for the quarter, compared to analysts’ expectations of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, sell-side analysts expect that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of STOK. Barclays PLC boosted its position in shares of Stoke Therapeutics by 145.3% in the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock worth $980,000 after purchasing an additional 47,239 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Stoke Therapeutics by 9.7% in the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock worth $10,705,000 after acquiring an additional 76,661 shares in the last quarter. State Street Corp boosted its holdings in Stoke Therapeutics by 8.6% in the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after acquiring an additional 137,145 shares in the last quarter. RTW Investments LP grew its stake in shares of Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after acquiring an additional 427,447 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of Stoke Therapeutics by 1,589.7% during the third quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock valued at $936,000 after acquiring an additional 71,647 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.